HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: CMA on NTP's triethanolamine (TEA) draft report

This article was originally published in The Rose Sheet

Executive Summary

CMA on NTP's triethanolamine (TEA) draft report: Chemical Manufacturers Association's "alkanolamines panel" will meet with the National Toxicology Program Feb. 28 to discuss the association's evaluation of NTP's draft technical report on the toxicology and carcinogenesis of TEA in rats and mice. According to NTP, a two-year study showed "some evidence" of carcinogenic activity in female mice dermally exposed to TEA "based on increased incidences of hepatocellular neoplasms" ("The Rose Sheet" May 15, p. 1). An independent consultant contracted by CMA found evidence of heliobacter hepaticus bacteria in frozen tissue samples obtained from NTP, thus, possibly confounding the NTP study results, according to CMA, since the bacteria has been shown to cause liver tumors. TEA is widely used in cosmetic formulations including emulsifiers and thickeners...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002533

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel